8-K: Vaccinex Announces Positive Clinical Findings for Pepinemab in Mild Cognitive Impairment Due to Alzheimer's Disease, Seeks Development Partnership

Vaccinex reports positive results from its SIGNAL-AD Phase 1b/2 trial, showing pepinemab slowed cognitive decline in patients with mild cognitive impairment due to Alzheimer's disease and plans to pursue a development partnership.

Summary

• Vaccinex has released new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab in Alzheimer's disease.
• The study showed a statistically significant difference in FDG-PET signal in the medial temporal cortex after 12 months of pepinemab treatment compared to placebo (p=0.0297).
• Pepinemab was well-tolerated in Alzheimer's patients, consistent with previous trials in Huntington's disease.
• The trial focused on changes in blood biomarkers, specifically GFAP and p-tau 217, which are associated with astrocyte reactivity and neuronal damage.
• The study found a positive correlation between GFAP and p-tau 217 levels in blood over 12 months of treatment (correlation coefficient >0.5, p<0.001).
• Pepinemab treatment reduced the increase in GFAP levels in blood in patients with mild cognitive impairment (MCI) due to Alzheimer's disease.
• The study also showed a trend of cognitive benefit from pepinemab treatment in patients with MCI, supported by statistically significant results from a previous study in Huntington's disease (p=0.007).
• The company believes that pepinemab treatment is beneficial for patients with MCI due to Alzheimer's disease, but the benefit is reduced in patients with more advanced dementia.
• MCI is estimated to affect 1 million people with Alzheimer's disease in the US alone.
• Vaccinex is seeking a major partnership for continued development of pepinemab, aiming to reduce operating expenses.

Sentiment

Score: 7

Explanation: The document presents positive clinical data and a clear path forward with a partnership strategy, but there are still risks associated with clinical trials and regulatory approval. The sentiment is positive but tempered by the inherent uncertainties in drug development.

Positives

• The study demonstrated a statistically significant improvement in brain metabolic activity in the medial temporal cortex with pepinemab treatment.
• Pepinemab showed a positive impact on blood biomarkers associated with astrocyte reactivity and neuronal damage.
• The treatment appears to slow cognitive decline in patients with mild cognitive impairment due to Alzheimer's disease.
• The company is actively seeking a partnership to advance the development of pepinemab, which could reduce operating expenses.
• The drug was well tolerated in the study.

Negatives

• The study found no discernible effect of pepinemab treatment on GFAP or p-tau 217 levels in blood of patients with more advanced early dementia.
• The cognitive benefit of pepinemab appears to be reduced or lost as the disease progresses from MCI to dementia.

Risks

• The company's future success is dependent on securing a major partnership for continued development of pepinemab.
• There are risks associated with the execution, cost, and completion of clinical trials.
• Interim and preliminary data may not be predictive of final results.
• Regulatory approval is not guaranteed.
• The company is dependent on its lead product candidate, pepinemab.
• There is a risk of delisting from Nasdaq if the company cannot maintain compliance with listing standards.

Future Outlook

The company plans to pursue a major partnership for the continued development of pepinemab and intends to report further details and outcomes of the SIGNAL-AD trial at upcoming scientific conferences and in a medical journal. The company believes that a drug that can slow or halt progression from MCI to dementia represents the most promising potential treatment option for AD.

Management Comments

• Maurice Zauderer, PhD, President & CEO of Vaccinex, stated that the company has compiled compelling early phase evidence of favorable tolerability and efficacy of pepinemab in neurodegenerative disease.
• Maurice Zauderer, PhD, President & CEO of Vaccinex, expressed gratitude for past investor support and confidence in the company's future.

Industry Context

The announcement is significant in the context of the ongoing search for effective treatments for Alzheimer's disease, particularly in the early stages of the disease. The focus on MCI is aligned with the industry's growing recognition of the importance of early intervention. The company's strategy to seek a partnership is a common approach in the biotech industry to share the costs and risks of late-stage drug development.

Comparison to Industry Standards

• The use of FDG-PET imaging to measure brain metabolic activity is a standard practice in Alzheimer's disease research, and the statistically significant difference observed in the medial temporal cortex is a positive indicator.
• The focus on blood-based biomarkers like GFAP and p-tau 217 aligns with the industry's trend towards less invasive diagnostic and monitoring tools.
• The company's approach of targeting astrocyte reactivity is a novel approach compared to other companies that focus on amyloid plaques or tau tangles.
• Eli Lilly's iADRS cognitive assessment is a well-known and respected tool in the industry, and the use of ADAS-Cog 13 provides additional validation of the cognitive results.
• The company's results in MCI are comparable to other companies that are developing drugs for early-stage Alzheimer's disease, such as Biogen and Eisai with their drug Lecanemab, which has shown some efficacy in slowing cognitive decline in early AD.

Stakeholder Impact

• Shareholders may view the positive clinical results and partnership strategy favorably.
• Patients with mild cognitive impairment due to Alzheimer's disease may benefit from the potential development of pepinemab.
• Employees may be impacted by the company's partnership strategy and potential changes in operating expenses.
• Potential partners may be interested in the company's clinical data and development strategy.

Next Steps

• The company plans to report further details and outcomes of the SIGNAL-AD trial at upcoming scientific conferences.
• The company plans to publish a complete study report in a medical journal.
• The company will seek a major partnership for continued development of pepinemab.

Key Dates

Keywords

pepinemab, Alzheimer's disease, mild cognitive impairment, Huntington's disease, clinical trial, biomarkers, cognitive decline, FDG-PET, GFAP, p-tau 217, neurodegenerative disease, partnership